Camp d’exploration sur la survie sans progression à faible objectif : une survie sans progression supérieure à 18 mois ! Le traitement de deuxième ligne par dabrafénib et tramétinib améliore significativement la survie des patients atteints d’un cancer du poumon non à petites cellules (CPNPC) avancé porteur de la mutation BRAF V600E – Oncology Information
「少靶真探营」PFS 超18 个月！达拉非尼+ 曲美替尼二线治疗强效增进晚期BRAF V600E突变NSCLC患者生存延长 肿瘤资讯
该文章暂未提取到完整正文，已从资讯列表和商品关联资讯中自动隐藏。你可以返回文章列表继续浏览其他内容。
Questions frequentes
Which products are related to this article?
No strongly related product has been identified yet. The match updates automatically when the article or catalog changes.
How can I view the medicines discussed in this article?
Use the related product cards below the article to review available specifications, prices, product information, and reviews.
Does this article replace advice from a doctor or pharmacist?
No. This content is for general information and health education only. Follow the prescription and individual guidance provided by qualified healthcare professionals.
